Trial Profile
An expanded access study of post-transplant relapsed pediatric patients receiving blinatumomab
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 30 Dec 2015
Price :
$35
*
At a glance
- Drugs Blinatumomab (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Expanded access; Therapeutic Use
- 30 Dec 2015 New trial record